Prevention of Cervical Cancer Through an HPV-based Screen-and-treat Strategy in Malawi

November 3, 2023 updated by: University of North Carolina, Chapel Hill

UNCPM 21904 - Prevention of Cervical Cancer Through an HPV-based Screen-and-treat Strategy in Malawi: a Cluster Randomized Trial

The purpose of the study is to determine the acceptability, appropriateness, and feasibility of implementing new strategies to screen and treat eligible women for cervical cancer through a cluster randomized trial of two different models. Both models offer the same screening and treatment algorithm, but one will be based in Voluntary Family Planning (VFP) or other clinics and the second will be based in the community. Participants will be recruited from two districts in Malawi with the highest HIV prevalence in the country: Lilongwe in the Central Region and Zomba in the Southern Region.

Study Overview

Detailed Description

Cervical cancer is largely preventable through screening and preventive therapy. This is a cluster randomized trial that will integrate a novel cervical cancer screen-and-treat algorithm into voluntary family planning (VFP) services via two different models aimed at reducing barriers to screening and treatment in resource limited settings. Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day visual inspection with acetic acid (VIA) for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA. Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive. Participants will be recruited from 16 high HIV-prevalence clinics in either Lilongwe in the Central Region or Zomba in the Southern Region. The broad objective of the project is to compare the effectiveness and budget impact of these two models for averting potential cervical cancer cases and to evaluate the implementation and acceptability of the models in multiple different health care facility settings.

A systematic Implementation Evaluation will be conducted throughout implementation of the assigned models at the study health facilities to determine the success/failure in the delivery of intervention packages. The study team will employ the following mixed method data collection assessments:

  • In-Depth Interviews with purposively selected healthcare facility staff and clients in the sampled facilities (N = approximately 60).
  • Focus group discussions (FGDs) with purposively selected in-clinic services providers and HSAs (N = approximately 160).
  • Structured weekly observations of service delivery by clinical mentors using an observation checklist, to observe providers and laboratorians adherence to standards, guidelines and intervention protocols.
  • Aggregate collection of routine quantitative service utilization data from adapted family planning and cervical cancer screening registers.
  • Implementation of assessment tools to assess changes in service providers' workload.
  • Client Exit Surveys with women in the catchment areas of the targeted facilities who received or declined family planning and/or cervical cancer screening services at the facility or in the community (N= approximately 1,000).
  • Time and motion studies to observe visits and staff time spent on counseling, screening and treatment procedures, and managing and testing specimens.

Finally, an Endline Household Survey will be completed among a random sample of women selected from all of the facilities' catchment areas (N= approximately 8,000). This survey will ask questions about basic demographic information, reproductive health information, HIV status, distance to the nearest health facility, prior VFP use, VFP use during project implementation, prior cervical cancer screening and preventive therapy (CCSPT) services received, and any CCSPT services received during project implementation.

Study Type

Interventional

Enrollment (Actual)

8174

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lilongwe, Malawi
        • UNC Project-Malawi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 50 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Health care providers In-Depth Interviews (IDIs) and Focus Group Discussions:

  • Health care staff member must be currently working at one of the 16 health facilities selected for the study.

Client In-Depth Interviews:

  • Woman must have participated in cervical cancer screening via HPV self-sampling through one of the 16 health facilities during the study period.

Client Exit Surveys:

  • Woman who received or declined VFP and/or CCS services in the catchment area of the targeted facilities.

Endline Household survey:

  • Woman must be between the ages of 15-50 years.

Exclusion Criteria:

Endline Household survey:

  • Woman who has had her cervix removed.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Model 1 - Clinic Based Screening
Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA
Offering HPV self-collection for cervical cancer screening in the clinic
Experimental: Model 2 - Community Based Screening
Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive
Offering HPV self-collection for cervical cancer screening in the community

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of women who receive cervical cancer screening in Model 2
Time Frame: 12 months after model implementation
Effectiveness of community-based cervical cancer screening as measured through Endline Household Surveys
12 months after model implementation
Proportion of women who receive family planning services in Model 2
Time Frame: 12 months after model implementation
Effectiveness of integrating community-based cervical cancer screening into family planning services as measured through Endline Household Surveys
12 months after model implementation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of healthcare workers who report satisfaction with providing cervical cancer services
Time Frame: 12 months after model implementation
Acceptability and feasibility of service provision as measured through routine assessments
12 months after model implementation
Proportion of healthcare workers who report satisfaction with providing family planning services
Time Frame: 12 months after model implementation
Acceptability and feasibility of service provision as measured through routine assessments
12 months after model implementation
Proportion of clients who report satisfaction with cervical cancer services received at study facilities
Time Frame: 12 months after model implementation
Acceptability and feasibility of cervical cancer screening and preventive therapy as measured through client exit surveys
12 months after model implementation
Proportion of clients who report satisfaction with family planning services received at study facilities
Time Frame: 12 months after model implementation
Acceptability of family planning services as measured through client exit surveys
12 months after model implementation
Cost of the intervention
Time Frame: 12 months after model implementation
The cost per client of adding cervical cancer screening and preventive therapy to voluntary family planning services in each model as measured through routine assessments and client exit surveys
12 months after model implementation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jennifer Tang, MD, MSCR, University of North Carolina, Chapel Hill

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 4, 2020

Primary Completion (Actual)

December 18, 2021

Study Completion (Actual)

December 18, 2021

Study Registration Dates

First Submitted

February 24, 2020

First Submitted That Met QC Criteria

February 24, 2020

First Posted (Actual)

February 26, 2020

Study Record Updates

Last Update Posted (Actual)

November 7, 2023

Last Update Submitted That Met QC Criteria

November 3, 2023

Last Verified

May 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Research data that documents, supports, and validates research findings will be made available after the main findings from the final research dataset have been accepted for publication. Access to databases will be available for educational, research, and non-profit purposes. All data to be shared will be stripped of any potentially identifying information. Data will be made available through USAID's Data Development Library (DDL).

IPD Sharing Time Frame

Data will be available within 6 months of publication for an unlimited period

IPD Sharing Access Criteria

Deidentified data will be publicly available through the DDL. Research datasets may also be made available to Malawian and other international investigators who request access. Requests will be evaluated on a case-by-case basis by the study investigators.

Investigators proposing to use the data will be asked to provide approval from an ethical review committee and may be asked to execute a data use/sharing agreement with UNC. Data may be shared electronically via password protected files.

All data sharing will abide by rules and/or policies defined by USAID, relevant IRBs, U.S. local, state, and federal laws and regulations, as well as Malawian laws and regulations. Data sharing mechanisms will ensure that the rights and privacy of individuals participating in research will be protected at all times.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Clinical Trials on Clinic-based HPV screening strategy

Subscribe